Adamas Pharmaceuticals (NASDAQ:ADMS) Lowered to Hold at Zacks Investment Research
According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
Several other research analysts have also recently issued reports on the company. ValuEngine cut Zosano Pharma from a buy rating to a hold rating in a research note on Wednesday, May 1st. Mizuho restated a buy rating and issued a $37.00 price objective on shares of Revance Therapeutics in a research note on Wednesday, April 24th. Finally, HC Wainwright set a $55.00 price objective on Acer Therapeutics and gave the stock a buy rating in a research note on Tuesday, May 28th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $18.91.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.05. Adamas Pharmaceuticals had a negative return on equity of 122.40% and a negative net margin of 291.22%. The firm had revenue of $11.67 million during the quarter, compared to analysts’ expectations of $12.78 million. Equities research analysts predict that Adamas Pharmaceuticals will post -3.77 earnings per share for the current year.
Several large investors have recently made changes to their positions in the company. Broadfin Capital LLC grew its holdings in Adamas Pharmaceuticals by 96.8% during the fourth quarter. Broadfin Capital LLC now owns 2,614,468 shares of the specialty pharmaceutical company’s stock worth $22,328,000 after acquiring an additional 1,286,044 shares during the period. Macquarie Group Ltd. grew its holdings in Adamas Pharmaceuticals by 51.7% during the fourth quarter. Macquarie Group Ltd. now owns 2,708,217 shares of the specialty pharmaceutical company’s stock worth $23,128,000 after acquiring an additional 923,099 shares during the period. Deltec Asset Management LLC grew its holdings in Adamas Pharmaceuticals by 127.4% during the first quarter. Deltec Asset Management LLC now owns 536,836 shares of the specialty pharmaceutical company’s stock worth $3,817,000 after acquiring an additional 300,712 shares during the period. Millennium Management LLC grew its holdings in Adamas Pharmaceuticals by 91.6% during the fourth quarter. Millennium Management LLC now owns 479,899 shares of the specialty pharmaceutical company’s stock worth $4,098,000 after acquiring an additional 229,404 shares during the period. Finally, Deutsche Bank AG grew its holdings in Adamas Pharmaceuticals by 506.7% during the fourth quarter. Deutsche Bank AG now owns 274,050 shares of the specialty pharmaceutical company’s stock worth $2,339,000 after acquiring an additional 228,883 shares during the period. Hedge funds and other institutional investors own 76.68% of the company’s stock.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
See Also: How does a reverse stock split work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.